Russian medicine on antibodies against covid will begin to be tested in St. Petersburg this year. Testing is expected to be completed in 2023.
Experts from one of the institutes of the Russian Academy of Sciences have created a gene method for creating antibodies that react to various strains of covid. Before the end of this year, preclinical studies of this drug will start in St. Petersburg, which may become the first domestic drug for coronavirus. Information about this was reported by one of the developers of the drug, Sergei Guselnikov.
In the United States urgently approved a drug for coronavirus
The tests will take place at the Institute of Molecular and Cellular Biology of the Siberian Branch of the Russian Academy of Sciences. Its employees have created a technology that makes it possible to obtain antibodies to the coronavirus. For this, genetic technologies of the latest generations are used. In the coming months, as Sergei Guselnikov said, the creators of the drug are preparing to obtain producers, as well as antibodies that will be transferred to the St. Petersburg Institute of Influenza, on the basis of which preclinical studies will be carried out. COVID-19
It is expected that they will begin in 2022 and end as early as 2023. We note that until recently our country did not have its own development of drugs for the specific treatment of coronavirus, except for Russian analogues of the Japanese favipiravir. However, areplivir and similar drugs do not have a proven effect in accordance with international clinical standards, and many even Russian experts highly doubt that these drugs really help. There is also a point of view that areplivir is dangerous for the health of patients with coronavirus and other people. (READ MORE) 
Sergey Guselnikov Medicine Senior Researcher, Laboratory of Antibody Engineering, IMKB SB RAS